QQ客服 官方微博 反馈留言

浏览/检索结果: 共8条，第1-8条 帮助 限定条件 专题：山东大学    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 The efficacy of anlotinib in squamous cell carcinoma (SCC) patients with or without hypertension in ALTER0303: Anlotinib as a third-line therapy in patients with advanced non-small cell lung cancer (NSCLC). 会议论文 Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), MAY 31-JUN 04, 2019 作者:  Shi, Jianhua;  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhang, Li 收藏  |  浏览/下载：5/0  |  提交时间：2019/12/31 The Society for Translational Medicine: indications and methods of percutaneous transthoracic needle biopsy for diagnosis of lung cancer 期刊论文 JOURNAL OF THORACIC DISEASE, 2018, 卷号: 10, 期号: 9, 页码: 5538-5544 作者:  Zhou, Qinghua;  Dong, Jingsi;  He, Jie;  Liu, Deruo;  Tian, David H. 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/11 Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial 期刊论文 JAMA ONCOLOGY, 2018, 卷号: 4, 期号: 11, 页码: 1569-1575 作者:  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua 收藏  |  浏览/下载：1/0  |  提交时间：2019/12/11 Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment 期刊论文 CANCER BIOLOGY & MEDICINE, 2018, 卷号: 15, 期号: 4, 页码: 443-451 作者:  Wang, Jing;  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/11 Society for Translational Medicine expert consensus on training and certification standards for surgeons and assistants in minimally invasive surgery for lung cancer 期刊论文 JOURNAL OF THORACIC DISEASE, 2018, 卷号: 10, 期号: 10, 页码: 5666-5672 作者:  Liu, Lunxu;  Mei, Jiandong;  He, Jie;  Gao, Shugeng;  Li, Shanqing 收藏  |  浏览/下载：6/0  |  提交时间：2019/12/11 Society for Translational Medicine Expert Consensus on the preoperative assessment of circulatory and cardiac functions and criteria for the assessment of risk factors in patients with lung cancer 期刊论文 JOURNAL OF THORACIC DISEASE, 2018, 卷号: 10, 期号: 9, 页码: 5545-5549 作者:  Liu, Deruo;  Wen, Huanshun;  He, Jie;  Gao, Shugeng;  Li, Shanqing 收藏  |  浏览/下载：8/0  |  提交时间：2019/12/11 Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study 期刊论文 LANCET ONCOLOGY, 2017, 卷号: 18, 页码: S3-S3 作者:  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhao, Yizhuo;  Zhang, Li 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/16 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2017, 卷号: 12, 期号: 1, 页码: S886-S887 作者:  Han, Baohui;  Li, Kai;  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/12 NSCLC  Anlotinib  multi-targeted tyrosine kinase inhibitor